Status:
COMPLETED
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Candidiasis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the safety and effectiveness of 2 treatments to prevent invasive fungal infections (IFI), which are infections caused by yeasts and molds that are common in pat...
Detailed Description
If you are in the high risk group you will be assigned randomly (like tossing a coin) to receive either AmBisome or fluconazole. If you are in the low risk group, you will not receive any treatment. B...
Eligibility Criteria
Inclusion Criteria:
You may be eligible for this study if you:
- Have had a liver transplant within 5 days of enrollment and agree to receive tacrolimus.
Exclusion Criteria:
You will not be eligible for this study if you:
- Are HIV-positive.
- Have a history of invasive fungal infection.
- Have received antifungal agents within 14 days prior to your liver transplant.
- Are allergic to azoles, amphotericin B, or tacrolimus.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00001107
End Date
November 1 2005
Last Update
August 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mary Ellen Bradley
Birmingham, Alabama, United States, 35294